Afatinib Terminated Phase 4 Trials for ErbB Receptors / Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT02695290Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)